The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase II trial of the MEK1/2 inhibitor selumetinib (AZD6244) in adults with neurofibromatosis type 1 (NF1) and inoperable plexiform neurofibromas (PNs).
 
Diana Bradford
No Relationships to Disclose
 
Patricia Whitcomb
No Relationships to Disclose
 
Eva Dombi
No Relationships to Disclose
 
Alice P. Chen
No Relationships to Disclose
 
Andrea Baldwin
No Relationships to Disclose
 
Pamela Wolters
Stock and Other Ownership Interests - Bristol-Myers Squibb
 
Staci Martin
No Relationships to Disclose
 
John Glod
No Relationships to Disclose
 
Joanne Derdak
No Relationships to Disclose
 
Geraldine Helen O'Sullivan Coyne
No Relationships to Disclose
 
Edward W. Cowen
No Relationships to Disclose
 
Marielle Holmblad
No Relationships to Disclose
 
Jane Trepel
Research Funding - Macrogenics (Inst); Syndax (Inst)
Patents, Royalties, Other Intellectual Property - NIH (Inst)
 
Bradford J. Wood
No Relationships to Disclose
 
Scott M. Paul
No Relationships to Disclose
 
Wade Clapp
No Relationships to Disclose
 
Gary L. Johnson
No Relationships to Disclose
 
Larry Rubinstein
No Relationships to Disclose
 
L. Austin Doyle
No Relationships to Disclose
 
Brigitte C. Widemann
No Relationships to Disclose